Want to see BHST full AI Analyst Report?
Top Page
BioHarvest Sciences
(NASDAQ:BHST)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-25.00% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial quality (ongoing losses and persistent cash burn) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting factors include strong gross margins and revenue progress, plus earnings-call positives around improved cash and longer-term CDMO opportunity—though these are tempered by lowered 2026 guidance and continued EBITDA losses.
Positive Factors
Strong Revenue Growth and Gross Margin
Revenue has reached $35.5M TTM, up about 92% year over year, while gross margin is near 59%. This combination indicates meaningful product demand and attractive unit economics, giving BHST a stronger base to fund commercialization and pursue scale, even before profitability.
Negative Factors
Persistent Losses and Cash Burn
BHST continues to consume cash while operating at a meaningful net loss, showing that revenue growth and gross margin have not yet translated into self-funded operations. Sustained burn may require financing or balance-sheet capacity, limiting flexibility until the business reaches break-even.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth and Gross Margin
Revenue has reached $35.5M TTM, up about 92% year over year, while gross margin is near 59%. This combination indicates meaningful product demand and attractive unit economics, giving BHST a stronger base to fund commercialization and pursue scale, even before profitability.
Read all positive factors
BioHarvest Sciences (BHST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.72M
Dividend YieldN/A
Average Volume (3M)29.38K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth17.50%
EPS Growth24.63%
CountryUS
Employees89
SectorConsumer Defensive
Sector Strength42
IndustryAgricultural - Commodities/Milling
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume25,195
30 Day Avg. Volume29,382
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit3.16
Enterprise Value/Ebitda-9.07
Forecast
1Y Price Target
$9.00Price Target Upside350.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$42.89M
BioHarvest Sciences Business Overview & Revenue Model
Company Description
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingred...
How the Company Makes Money
BioHarvest Sciences primarily makes money by selling products derived from its proprietary plant-cell cultivation (“botanical synthesis”) technology. Its revenue model is based on (1) direct sales of finished nutraceutical/health-and-wellness prod...
BioHarvest Sciences Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 30, 2026
Earnings Call Sentiment Neutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.Positive Updates
First Major CDMO Manufacturing & Supply Agreement
Signed first-ever CDMO manufacturing and supply agreement for a UAE-based customer for a rare luxury fragrance with a 20-ton commitment. Company states potential to translate to $20 million to $30 million in revenue across 2027–2028 and signaled an expectation of ~$180 million for the first five years of manufacturing for this fragrance category.
Negative Updates
Total Revenue Guidance Reduced
Full-year consolidated revenue guidance lowered to $37 million–$40 million from prior range of $42 million–$48 million, reflecting reallocation of spend toward CDMO capacity build-out and conservative go-to-market investments.
Read all updates
Q2-2026 Updates
Positive
Negative
First Major CDMO Manufacturing & Supply Agreement
Signed first-ever CDMO manufacturing and supply agreement for a UAE-based customer for a rare luxury fragrance with a 20-ton commitment. Company states potential to translate to $20 million to $30 million in revenue across 2027–2028 and signaled an expectation of ~$180 million for the first five years of manufacturing for this fragrance category.
Read all positive updates
Company Guidance
Management tightened 2026 guidance, lowering consolidated revenue to $37–$40M (from $42–$48M) while still targeting consolidated EBITDA breakeven in 2027 and forecasting a consolidated EBITDA loss of $3–$5M (was $3–$4M); CDMO revenue was tightened to $4–$5M (from $4–$6M) with CDMO full‑year EBITDA loss cut to $1.5–$2.5M (from $4–$5M). The VINIA D2C business was revised to $33–$35M in revenue (from $38–$42M) with an expected EBITDA loss of $1.5–$2.5M (priorly a $0.5–$2M gain); VINIA has ~95,000 active customers (up ~2% YoY and vs Q1), implemented up to 20% pricing increases for certain new subscribers in June, and will launch single‑dose Daily Chews in September. Management expects limited production and revenue recognition for the new 20‑ton fragrance CDMO supply agreement to begin in H1 2027 and says the deal could translate to $20–$30M of revenue in 2027–2028 (and previously projected ~$180M over the first five years), while cash and deposits stood at $16.2M at June 30, 2026 (vs $3.7M a year earlier); Q2 results included revenue of $8.8M (+3.8% YoY), gross profit $5.1M (58% margin), net loss $3.7M ($0.17/sh), and adjusted EBITDA loss $1.6M.BioHarvest Sciences Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
41
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.48M | 34.51M | 25.19M | 12.67M | 5.50M | 2.10M |
| Gross Profit | 20.91M | 20.48M | 13.94M | 5.63M | 1.22M | 670.00K |
| EBITDA | -7.29M | -6.71M | -9.72M | -9.76M | -9.13M | -8.64M |
| Net Income | -11.07M | -11.13M | -12.91M | -12.56M | -11.24M | -9.83M |
Balance Sheet | ||||||
| Total Assets | 44.57M | 47.66M | 25.00M | 15.00M | 9.39M | 10.21M |
| Cash, Cash Equivalents and Short-Term Investments | 16.22M | 23.02M | 2.39M | 5.36M | 1.74M | 4.12M |
| Total Debt | 17.55M | 14.10M | 13.82M | 22.34M | 10.56M | 2.66M |
| Total Liabilities | 24.80M | 22.22M | 23.67M | 29.86M | 15.32M | 7.35M |
| Stockholders Equity | 19.76M | 25.45M | 1.33M | -14.85M | -5.93M | 2.85M |
Cash Flow | ||||||
| Free Cash Flow | -10.95M | -9.58M | -9.52M | -10.00M | -10.50M | -8.43M |
| Operating Cash Flow | -8.71M | -7.23M | -6.68M | -8.52M | -9.24M | -6.79M |
| Investing Cash Flow | -3.25M | -2.37M | -3.03M | -1.47M | -1.26M | -1.64M |
| Financing Cash Flow | 23.50M | 30.19M | 6.78M | 13.56M | 8.14M | 10.77M |
BioHarvest Sciences Technical Analysis
Positive
2.00
Price Trends
1.83
Negative
2.41
Negative
3.49
Negative
Market Momentum
-0.08
Negative
48.47
Neutral
74.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BHST, the sentiment is Positive. The current price of 2 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.83, and below the 200-day MA of 3.49, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 48.47 is Neutral, neither overbought nor oversold. The STOCH value of 74.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BHST.
BioHarvest Sciences Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $8.88B | 8.81 | 4.08% | 0.64% | 3.70% | -26.39% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
44 Neutral | $1.29B | -0.38 | -118.57% | 3.85% | -21.31% | -2884.91% | |
44 Neutral | $8.62M | -1.08 | 39.83% | ― | -25.50% | -905.27% | |
42 Neutral | $36.72M | -3.00 | -58.30% | ― | 17.50% | 24.63% | |
40 Underperform | $544.48K | -0.03 | -339.85% | ― | -12.24% | 17.56% | |
34 Underperform | $20.93M | -0.09 | -216.09% | ― | -26.10% | 14.85% |
* Consumer Defensive Sector Average
BHST
BioHarvest Sciences
1.82
-10.21
-84.87%
FMC
FMC
8.31
-21.31
-71.94%
SEED
Origin Agritech
0.73
-0.71
-49.48%
RKDA
Arcadia Biosciences
0.21
-3.48
-94.39%
BIOX
Bioceres Crop Solutions
0.33
-1.22
-78.90%
CTVA
Corteva
13.36
4.05
43.44%
BioHarvest Sciences Corporate Events
BioHarvest Sciences Launches 5% Share Buyback to Capitalize on Perceived Undervaluation
Oct 2, 2026
BioHarvest Sciences announced on September 29, 2026 that its board has approved a normal course issuer bid share repurchase program, allowing the company to buy back up to 5% of its outstanding common shares, or 1,133,392 shares, over a 12‑m...
BioHarvest Launches VINIA Daily Chews to Expand Botanical Synthesis Footprint
Sep 15, 2026
BioHarvest Sciences has introduced single‑dose VINIA Daily Chews, a new chewable format of its proprietary red‑grape cell composition, on September 15, 2026. The product, delivering 400 mg of VINIA and 6 mg of piceid resveratrol per ch...
BioHarvest Sciences Secures Dual Listing on Tel Aviv Stock Exchange
Sep 15, 2026
BioHarvest Sciences Inc., a Vancouver-based foreign private issuer listed on the Nasdaq Capital Market, reported details of its capital structure in connection with a new exchange listing. The company’s 22.7 million outstanding common shares...
BioHarvest Sciences Showcases Botanical Synthesis Progress at H.C. Wainwright Global Investment Conference
Sep 14, 2026
BioHarvest Sciences Inc. announced on September 14, 2026, that CEO Zaki Rakib will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, held from September 14–16, 2026. The in-person company presentation is sc...
BioHarvest Secures First CDMO Manufacturing Deal and Posts Modest Q2 Revenue Growth
Aug 12, 2026
On August 11, 2026, BioHarvest Sciences reported second-quarter 2026 revenue of $8.8 million, up 3.8% year-on-year, with gross margins of 58% and a net loss narrowed to $3.7 million, while operating losses and adjusted EBITDA loss increased as the...
BioHarvest Sciences Files Q2 2026 Interim Financials and MD&A
Aug 11, 2026
BioHarvest Sciences Inc. filed a Form 6-K for August 2026, providing investors with unaudited interim condensed consolidated financial statements and related disclosures for the three and six months ended June 30, 2026. The filing underscores the ...
BioHarvest Sciences to Spotlight Botanical Synthesis Platform at Canaccord Genuity Growth Conference
Jul 29, 2026
BioHarvest Sciences announced on July 29, 2026, that CEO Zaki Rakib will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, a key forum for global institutional investors focused on growth companies in technology, healthcare...
BioHarvest Sciences Sets August 11 Date for Q2 2026 Results and Investor Call
Jul 28, 2026
BioHarvest Sciences announced on July 28, 2026, that it will release its second quarter 2026 financial results before market open on Tuesday, August 11, 2026. The company will hold a conference call and webcast at 8:00 a.m. Eastern Time the same d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.